RNS Number: 4029 Z Indivior PLC 17 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1647 Z Indivior PLC 16 May 2019 Indivior to Participate in Jefferies 2019 Healthcare Conference. Slough, UK and Richmond, VA- May 16, 2019- Indivior PLC today announced that Shaun Thaxter, Chief Executive Officer, and Mark Crossley, Chief Financial Officer, will participate in Jefferies 2019 Healthcare Conference taking place in New York City on June 4...
Faruqi& Faruqi, LLP, a leading national securities law firm, reminds investors in Indivior PLC of the June 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Indivior stock or options between March 10, 2015 and April 9, 2019 and would like to discuss your legal rights,...
The Company has a sponsored Level 1 American Depositary Receipt facility in the United States, with each ADR representing five Ordinary Shares of US $0.10 each in the Company. The Company announces that it received notification on May 13, 2019 that Daniel Phelan, Non-Executive Director, acquired 10,000 ADRs, representing 50,000 Shares at an average price of...
RNS Number: 8624 Y Indivior PLC 13 May 2019 INDIVIOR PLC. The Company announces that it received notification on May 13, 2019 that Lorna Parker, a Non-Executive Director of the Company, acquired 11,529 shares at a price of £0.433655 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7442 Y Indivior PLC 13 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7443 Y Indivior PLC 13 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Indivior Enters into Exclusive License Agreement with HLS Therapeutics for PERSERIS™ in Canada. Slough, UK and Richmond, VA, May 9, 2019- Indivior PLC today announced that it has entered into a definitive license agreement with HLS Therapeutics Inc. for exclusive commercialization rights to PERSERIS™ in Canada.. Commercially, if approved, PERSERIS TM would be...
RNS Number: 5129 Y Indivior PLC 09 May 2019 BLOCK LISTING SIX MONTHLY RETURN. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
The law firm of Lieff Cabraser Heimann& Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Indivior PLC between March 10, 2015 and April 9, 2019, inclusive. If you purchased or otherwise acquired Indivior securities during the Class Period, you may move the Court...
The law firm of Lieff Cabraser Heimann& Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Indivior PLC between March 10, 2015 and April 9, 2019, inclusive. If you purchased or otherwise acquired Indivior securities during the Class Period, you may move the Court...
RNS Number: 4003 Y Indivior PLC 08 May 2019 Indivior PLC. Poll results of 5th Annual General Meeting. As at the close of business on May 3, 2019, the total number of ordinary shares of US $0.10 each eligible to be voted at the AGM was 730,030,588.
Glancy Prongay& Murray LLP reminds investors of the upcoming June 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Indivior PLC investors who purchased securities between March 10, 2015 and April 9, 2019, inclusive. On April 9, 2019, the U.S. Department of Justice announced that a federal grand jury had indicted Indivior“...
RNS Number: 9588 X Indivior PLC 03 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
On April 9, 2019, the U.S. Department of Justice announced that a federal grand jury had indicted Indivior“ for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” According to the indictment, Indivior deceived“ health care providers and health care benefit programs...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Indivior PLC from March 10, 2015 through April 9, 2019, inclusive of the important June 24, 2019 lead plaintiff deadline in the securities class action filed by the firm. The lawsuit seeks to recover damages for Indivior investors under the federal securities laws.
·Net revenue of $238 m declined 6%. U.S. net revenue grew 2% as SUBOXONE ® Film share loss was more than offset by underlying market growth, strong initial sell-in of the Group's authorized generic film product and net revenue from SUBLOCADE™. Rest of World net revenue declined primarily due to one-time net revenue gains in Canada in the prior period..
RNS Number: 8223 X Indivior PLC 02 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7240 X Indivior PLC 01 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Glancy Prongay& Murray LLP, a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Indivior PLC securities between March 10, 2015 and April 9, 2019, inclusive. On April 9, 2019, the U.S. Department of Justice announced that a federal grand jury had indicted Indivior“ for engaging in an...
Bid
--
-
Ask
- High-
- OPEN-
- VOL-
- MKT CAP-m
- LOW-
- CLOSE-
- AVG VOL-
- SHARES IN ISSUE730.03M
Company Profile
Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.
Classification
| Market Indices | - |
Locations
| HQ | 103-105 Bath Road SL1 3UH Slough |